|
|
|
| Correlation between Levels of Serum β2 Microglobulin Cystatin C and Serum α1 Microglobulin and Prognosis in Patients with Acute Renal Failure |
| XU Haibo, XU Liang, LIU Li |
| No.902 Hospital of the PLA Joint Logistics Support Force, Anhui Bengbu 233015, China |
|
|
|
|
Abstract Objective: To analyze the correlation between levels of serum β2 microglobulin (β2-MG), cystatin C (Cys C) and serum α1 microglobulin (α1-MG) and prognosis in patients with acute renal failure. Methods: The clinical data of 105 patients with acute renal failure who were treated between August 2020 and August 2021 were retrospectively analyzed. According to the severity of disease at admission, the patients were divided into stage I patients (n=41), stage II patients (n=40), and stage III patients (n=24). The differences in levels of serum β2-MG, Cys C and α1-MG at admission were compared among patients at different stages. According to the prognosis, the patients were classified into recovery group (patients with renal function recovery, n=67) and injury group (patients with permanent renal function injury, n=38). The differences in serum β2-MG, Cys C and α1-MG at admission among patients with different prognosis status were compared, and the evaluated efficiency of serum β2-MG, Cys C and α1-MG on the prognosis in patients with acute renal failure was explored. Results: The levels of serum β2-MG, Cys C and α1-MG in stage III patients were higher than those in stage II patients and stage I patients (P<0.05). The level of serum β2-MG and Cys C in stage II patients was higher than that in stage I patients (P<0.05). The levels of β2-MG, Cys C and α1-MG in recovery group were lower than those in injury group (P<0.05). Serum β2-MG, Cys C and α1-MG curves AUC were significantly higher than those of the reference lines (AUC>0.5), and their cut off values were 3.59mg/L, 3.21mg/L and 33.36mg/L respectively. Conclusion: Serum β2-MG, Cys C and α1-MG levels were correlated with the disease condition and the prognosis in patients with acute renal failure. It is necessary to take effective treatment measures before serum β2-MG level >3.59mg/L, Cys C level >3.21mg/L and α1-MG level >33.36mg/L in the clinical treatment of acute renal failure so as to improve the prognosis of patients.
|
|
|
|
|
|
[1] 陈树华,袁炜华,江小兰.血清胱抑素C、β2微球蛋白对早期糖尿病肾病的诊断价值[J].海南医学,2018,29(12):1693-1695.
[2] 张玉梅,赵曦雯,刘慧.糖尿病肾病患者血清同型半胱氨酸、胱抑素C和尿β2微球蛋白水平与肾功能指标的关系[J].中华高血压杂志,2018,26(9):879-882.
[3] 叶亮,李运泽,蒙毅军,等.尿微量白蛋白联合胱抑素C、α1微球蛋白、β2微球蛋白检测在早期肝肾综合征的诊断价值[J].中国中西医结合消化杂志,2021,29(12):894-899.
[4] 李向红,蔡丽军.血清胱抑素Cβ2-微球蛋白及血红蛋白水平评价高血压肾功能损害的临床价值[J].中国药物与临床,2019,19(12):2019-2021.
[5] 葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2018.518-523.
[6] 郭锦洲.改善全球肾脏病预后组织(KDIGO)临床实践指南:急性肾损伤[J].肾脏病与透析肾移植杂志,2013,22(1):57-60.
[7] 黎明,徐雯.血清同型半胱氨酸、血清胱抑素-C、尿β2-微球蛋白联合检测对早期诊断糖尿病肾病准确性分析[J].国际免疫学杂志,2018,41(4):430-433.
[8] 杜亚琴,张文松,牟俊杰,等.胱抑素C、β2微球蛋白和视黄醇结合蛋白的测定在评估慢性肾脏疾病损害程度中的应用[J].西部医学,2021,33(2):231-234.
[9] 王焕,崔凯,尤冠巧,等.血骨桥蛋白和胱抑素C联合检测在危重症急性肾损伤患者预后中的价值[J].中国中西医结合肾病杂志,2022,23(3):238-240.
[10] 庄苏园,王蒙蒙,董妍,等.急性肾损伤患者预后影响因素分析[J].医学研究生学报,2021,34(8):840-844.
[11] 聂丹阳,唐忠平,王河焱,等.不同时机启动肾脏替代治疗对急性肾损伤患者预后影响的Meta分析[J].重庆医学,2019,48(12):2070-2075. |
|
|
|
2023, Vol. 29 
